32222-47-2

Upstream product

• 52944-27-1 (R,S)-2-hydroxy-2-(3-aminophenyl)acetic acid 
• 100948-28-5 2-(3-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 
• 75-77-4 chloro-trimethyl-silane 
• 151-50-8 potassium cyanide 
• 456-48-4 3-Fluorobenzaldehyde 
• 143103-67-7 2-(3-fluorophenyl)-2-hydroxyacetonitrile 
• 455-36-7 1-(3-fluorophenyl)ethanone 
• 79477-87-5 2-(3-fluorophenyl)-2-oxoacetic acid 
• 32222-47-2 2-(3-fluorophenyl)-2-hydroxyacetic acid 
• 1384954-21-5 2-acetoxy-2-(3-fluorophenyl)acetic acid 
• 1170715-55-5 C₈H₆FNO 
• 773837-37-9 sodium cyanide 

Downstream Products

• 395-05-1 (2R)-2-(3-fluorophenyl)-2-hydroxyacetic acid 
• 79477-87-5 2-(3-fluorophenyl)-2-oxoacetic acid 
• 1072449-67-2 C₈H₆ClFO₂ 
• 456-48-4 3-Fluorobenzaldehyde 
• 455-37-8 3-fluorobenzamide 
• 395-05-1 (S)-2-(3-fluorophenyl)-2-hydroxyacetic acid 
• 25698-44-6 (R)-3-fluorophenylglycine 
• 1384954-21-5 2-acetoxy-2-(3-fluorophenyl)acetic acid 
• 17199-29-0 (S)-Mandelic acid 
• 611-71-2 (R)-Mandelic Acid 

Relevant academic research and scientific papers

PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders.

PERK INHIBITING COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

PERK INHIBITING INDOLINYL COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders, wherein Q is selected from (Ia), (Ib) ou (Ic).

PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):

PERK INHIBITORS FOR TREATING VIRAL INFECTIONS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to

PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS

The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.

The Synthesis of Chiral α-Aryl α-Hydroxy Carboxylic Acids via RuPHOX-Ru Catalyzed Asymmetric Hydrogenation

A ruthenocenyl phosphino-oxazoline-ruthenium complex (RuPHOX?Ru) catalyzed asymmetric hydrogenation of α-aryl keto acids has been successfully developed, affording the corresponding chiral α-aryl α-hydroxy carboxylic acids in high yields and with up to 97% ee. The reaction could be performed on a gram scale with a relatively low catalyst loading (up to 5000 S/C) and the resulting products can be transformed to several chiral building blocks, biologically active compounds and chiral drugs. (Figure presented.).

Enzymatic Resolution by a d-Lactate Oxidase Catalyzed Reaction for (S)-2-Hydroxycarboxylic Acids

Oxidase-catalyzed kinetic resolution is important for the production of enantiopure 2-hydroxycarboxylic acids (2-HAs), which are versatile building blocks for the synthesis of many significant compounds. However, in contrast to that of (R)-2-HAs, the production of (S)-2-HA is challenging because of the lack of related oxidases. Herein, suitable enzymes were screened systematically through the analysis of numerous putative d-lactate oxidase sequences and identification of several required properties. Finally, a d-lactate oxidase from Gluconobacter oxydans 621H with advantageous characteristics, such as good solubility, broad substrate spectrum, and high stereoselectivity, was selected to resolve 2-HAs into (S)-2-HAs. A variety of (S)-2-HAs was produced successfully using this d-lactate oxidase with excellent enantiomeric excess values (>99 %). The presented screening criteria and approach for target biocatalysis suggested a guideline for the production of optically active chemicals such as (S)-2-HAs.

Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis

The invention provides compositions comprising an alkene epoxidase and a selective epoxide hydrolase, such as a recombinant microorganism comprising a first heterologous nucleic acid encoding an alkene epoxidase and a second heterologous nucleic acid encoding a selective epoxide hydrolase. Exemplary alkene epoxidases include StyAB, while exemplary selective epoxide hydrolases include epoxide hydrolases from Sphingomonas, Solanum tuberosum, or Aspergillus. The invention also provides non-toxic methods of making enantiomerically pure vicinal diols or enantiomerically pure alpha-hydroxy carboxylic acids using these compositions and microorganisms.